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Coronary artery revascularization interventions, such as percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), and medical therapy are alternative approaches for treating coronary artery disease (CAD). Although PCI and CABG are among the most common medical procedures performed in the United States (1, 2) , uncertainty persists regarding their comparative effectiveness for stable CAD. When considering revascularization, randomized controlled trials have not found clear survival benefits for CABG over PCI (3) . Furthermore, except among subsets of patients with significant myocardium at risk (e.g., those with ischemic cardiomyopathy) (4), contemporary randomized controlled trials have not shown improved survival among patients with stable CAD receiving PCI or CABG compared with those receiving medical therapy. In contrast, observational studies have generally found statistically significant survival gains in favor of CABG and PCI (3) . Prominent explanations for these inconsistencies include the limited generalizability of clinical trial findings to the broader patient populations seen in clinical practice (and included in the observational studies) and confounding by unmeasured variables in observational studies (5, 6) .
Several requirements must be satisfied for valid causal inference in observational studies of fixed (point) exposures for CAD: The interventions and target of inference need to be well-defined; the compared groups should be exchangeable; the probability of being assigned to the interventions conditional on covariates needed for exchangeability should be positive; measurement error in exposure, outcome, and covariates should be accounted for; and missing data, including loss to follow-up, should be handled appropriately.
Some common approaches for estimating causal effects in observational studies of fixed exposures rely on the propensity score (7, 8) (i.e., the probability of receiving treatment conditional on covariates). In observational studies, the propensity score is unknown and has to be estimated, typically using a regression model for the probability of treatment conditional on baseline covariates. Careful consideration should be given to variable selection and other aspects of propensity score-model specification (9, 10) . The observed baseline covariates should be adequate for confounding control and the propensity score model should properly capture the covariatetreatment relationship in order to achieve covariate balance after using the estimated score. Examining balance in covariates between the groups allows an assessment of the propensity score model without using outcome information (11) . When imbalance is detected, analysts can modify the score (e.g., by including additional variables or product and nonlinear terms) and reassess balance; these steps can be iterated until balance is achieved. The final score model can then be used to estimate treatment effects via regression, matching, stratification, or inverse probability of treatment weighting (IPTW) (7, (12) (13) (14) (15) (16) . Overviews of studies using propensity scores to address confounding have often found that models are developed with a few haphazardly chosen predictors and simplistic model specifications (17) (18) (19) (20) (21) . Such propensity scores are unlikely to be adequate for achieving exchangeability of the compared groups and may even fail to produce balance in measured covariates.
We examined the conduct and reporting of comparative effectiveness analyses based on propensity scores in studies comparing CABG, PCI, or medical therapy for CAD. We also catalogued the covariates entered in different models to illustrate the diversity of model specifications in the literature and to inform the design of future studies using propensity scorebased methods.
METHODS

Study identification
We searched PubMed (January 2000 to February 2014) to identify studies of patients with CAD that compared treatments for CAD using propensity score-based methods. We used a combination of Medical Subject Headings (MeSH) terms and keywords related to CAD, the interventions, and the design and analysis methods of interest (see Web Appendix 1 (available at https://academic.oup.com/aje) for the complete search strategy).
Selection criteria
Studies were considered eligible if they used propensity score-based methods to compare at least 2 of the following major treatment strategies in adult patients with CAD: CABG (any method), PCI (with or without stents), or medical therapy. We also included studies that compared different stent types (e.g., bare-metal stent (BMS) vs. drug-eluting stent (DES)). We excluded comparisons of different techniques (e.g., on-pump vs. off-pump CABG; angiography vs. fractional flow reserveguided PCI; or radial vs. femoral access), subtypes of DES (e.g., paclitaxel-vs. sirolimus-eluting stents), joint interventions (e.g., CABG with carotid endarterectomy vs. CABG alone; or CABG with valve replacement vs. CABG alone vs. valve replacement alone), or past medical histories (e.g., CABG with vs. without prior PCI). We also excluded studies reporting that more than 30% of included patients presented with ST-segment-elevation acute coronary syndromes.
One reviewer (I.J.D.) screened titles and abstracts to select publications for further review. A second reviewer (A.G.E.) screened the full text of potentially eligible publications to determine whether they met the above inclusion criteria. All studies meeting the criteria were categorized as comparisons of CABG versus PCI, medical therapy versus CABG, medical therapy versus PCI, or among PCI approaches (e.g., BMS vs. DES, balloon angiography vs. DES). We extracted data from a random sample of 20 studies for each type of comparison or, when fewer than 20 studies were available, from all available studies. Web Appendix 2 lists eligible studies that were not selected for data extraction.
Data extraction
We created an electronic data extraction form using spreadsheet software (MS Excel; Microsoft Corporation, Redmond, Washington). A single reviewer (A.G.E.) entered data from 8 studies to pilot-test the form and revise its structure and content. The form was further modified with input from other investigators (I.J.D., T.A.T., B.S.W.), and the final version was used to extract data from all included studies. We extracted information on bibliographic details, study characteristics, patient selection criteria, characteristics of participants, interventions and outcomes assessed, and statistical methods. Specifically, we collected information on propensity score estimation, balance assessment, and estimation of treatment effects; sample size used for the propensity score development; variable selection approaches; the list of variables initially considered in the propensity score model; modeling methods; whether the propensity score model was modified by an iterative process to improve its performance (22, 23) ; whether and how discrimination and calibration were assessed; variables included in the final propensity score model; approach used to estimate the treatment effect (e.g., regression adjustment, matching, IPTW, stratification); methods for forming matched groups; and details about the estimation of causal effects.
With input from a cardiologist (B.S.W.), we organized the covariates included in the final propensity score model of all included studies into categories and more granular subcategories to explore patterns in variable selection across studies. For example, the category "CAD descriptors" contains 3 subcategories ("lesion characteristics," "location of diseased vessel," and "number of diseased vessels").
CABG with PCI (24-43), 20 comparing BMS with DES (44-63), 5 comparing CABG with medical therapy (64-68), 1 comparing PCI with medical therapy (69) , and 1 comparing DES with balloon angiography (70) . Figure 1 summarizes the study selection process.
Of the 20 publications addressing BMS versus DES, 1 estimated separate propensity scores and conducted separate analyses for patient cohorts with on-label and off-label indications for PCI (56) ; because these patient populations differed, we treated the 2 cohorts as separate studies. Another study estimated separate propensity scores for 2 treatment comparisons (paclitaxeleluting stents vs. BMS and sirolimus-eluting stents vs. BMS) (57) . We report information from that publication as a single study (of BMS vs. DES) because the modeling approach was identical across the 2 comparisons. Thus, our sample included data from 21 studies comparing BMS versus DES and 48 studies in total.
Characteristics of the included studies are summarized in Web Table 1 . Most studies enrolled patients from 2000 onward, although 6 studies began patient enrollment in the 1990s (1995 was the earliest enrollment year). Two-thirds of the included studies were published between 2010 and 2014. Studies often reported adequate information about PCI and CABG procedures but not about medical therapy. For example, only 1 study stated that medical therapy was consistent with "current standards of care" (patients received β-blockers, nitrates, aspirin, and statins). All studies assessed treatment effects on death from any cause except for a study that assessed only 1-year costs and another study that assessed only stroke outcomes.
Treatment effects on revascularization, myocardial infarction, stroke, and death due to cardiac causes were also commonly assessed.
Characteristics of included patient populations
Forty-six of the 48 studies restricted inclusion to patients with specific CAD characteristics or CAD-related events in their past medical history. For example, 8 studies selected participants on the basis of the number of affected coronary vessels, 14 on lesion location or other characteristics, and 16 on past history of revascularization. Several studies restricted participation on the basis of comorbidities or patient age (e.g., 7 studies included patients with diabetes, 3 included patients with renal disease, and 4 included elderly patients).
Propensity score estimation
Variable selection. Of the 48 studies, 15 did not report information about variable selection for the propensity score model (Table 1 ). Of the remaining 33 studies, 26 used a prespecified set of variables; 5 of these 26 reported using stepwise selection to determine whether to include product or nonlinear terms in the model. The remaining 7 studies, including 1 study that explicitly considered product terms, selected variables on the basis of statistical criteria for the association of covariates with treatment status (including backward or forward stepwise selection and significance testing of univariate associations).
Modification and iterative improvement of the propensity score model. One study explicitly did not expand the propensity score model with product or nonlinear terms because the authors found these terms unnecessary for achieving balance. No other studies reported modifying their propensity score models based on balance diagnostics.
Variables included in the final model. Ten studies did not explicitly report the variables included in the final propensity score model; for these studies, we assumed the variables listed in tables of baseline characteristics (typically "Table 1" and " Table 2 " of the publications) had been used. When relevant, we also considered each study's eligibility criteria as restrictions to a particular level of a potential confounding variable (see the "Characteristics of included patient populations" section above). We organized the more than 400 identified variables into 12 categories and 60 subcategories to ascertain overlap across studies. Web Figure 1 illustrates the variables used across the studies, according to treatment comparison. Variables commonly used across the models include age, sex, number and location of diseased vessels, prior myocardial infarction, prior CABG or PCI, diabetes, hypertension, and left ventricular ejection fraction. However, there was large variation in the variables selected across models; variables from any given subcategory were used in 1-45 of the 48 studies; variables from 43 subcategories were used in less than half of the studies.
Functional form of the final model (product and nonlinear terms). The propensity score was estimated using logistic regression in 42 studies and probit regression in 1 study; 5 studies did not provide that information. Only 9 of 48 studies reported including product or nonlinear terms in the final model. Of these 9 studies, 6 appeared to have based the decision to We extracted data from a random sample of 20 studies for each type of comparison or, when fewer than 20 studies were available, from all available studies. BMS, bare-metal stent; CABG, coronary artery bypass grafting; DES, drug-eluting stent; PCI, percutaneous coronary intervention. 
The propensity score was "modeled as a function of the potential confounders we identified and contained in our data set." (Clinical criteria.)
Examined the standardized differences between the stent groups (standardized differences <10% support balance). Examined the standardized differences between the stent groups (standardized differences <10% support balance). Examined the standardized differences in the observed confounders between the stent groups (standardized differences <10% support balance). include product or nonlinear terms on statistical criteria for the association of covariates with treatment; 1 reported examining "plausible interactions" but did not provide additional details; 1 reported including a prespecified product term between age and number of comorbidities; and 1 modeled continuous variables with linear and quadratic components. As noted above, 1 study explicitly reported not including product or nonlinear terms because balance was achieved with a simple model. The remaining 38 studies did not describe the final model used for estimating the score. Examination of propensity score distributions. Seven studies provided some description of the distribution of the estimated propensity score values among treatment groups (Table 1) . Of these, 1 study simply provided the mean values and standard deviations of the propensity scores for each treatment group; 1 described the propensity score distribution after matching had been performed; 3 reported excluding patients in (some of) the nonoverlapping portions of the distributions; and 2 did not exclude these patients. Two studies presented a figure of the propensity score distributions.
Discrimination and calibration assessment. Twenty-three studies did not report any assessment of the propensity score model discrimination or calibration. Twenty-five studies reported C statistic values, ranging from 0.66 to 0.98; 15 of these also reported using the Hosmer-Lemeshow statistic (Table 1) .
Balance assessment
Almost half of the studies (23, 48%) did not report any assessment of balance after the development of the propensity score. Of the remaining 25 studies, 23 used the propensity score to match treatment and control patients and presented tables containing the baseline characteristics of both the unmatched and matched cohorts (15 studies), tables with only the matched cohorts (5 studies), or only a narrative description of the balance assessment (3 studies). A single study, which used the propensity score as a covariate in an outcome regression model, described differences between treatment groups narratively. Another study, which used IPTW, presented baseline characteristics for the unweighted and weighted sample ( Table 1) .
Estimation of treatment effects using the propensity score
Of the 48 studies, 7 used the estimated propensity score in 2 or more different ways to estimate the treatment effect: 3 used matching and regression; 2 used matching and IPTW; 1 used stratification and regression; and 1 used matching, IPTW, and regression (Table 1) . Hence, we examined a total of 56 treatment effect analyses.
Matching (27 analyses). Where reported (23 of 27 analyses), propensity score matching was typically implemented through one-to-one matching using a greedy algorithm (Table 1) ; a single analysis minimized the Mahalanobis distance calculated from "key covariates" among patients having similar propensity scores. In the 19 analyses using matching within calipers, widths ranged from 0.001 to 0.1 of the estimated propensity scores (11 studies), 0.2-0.6 standard deviations of the logit-transformed propensity score (6 studies), or 0.25 standard deviations of the propensity score (2 studies). In addition to the propensity score, 2 analyses also matched exactly on additional covariates (e.g., race, unstable angina, index year). Twelve of 27 analyses (44%) reported using methods that accounted for matching. Stratification (5 analyses). Five analyses estimated treatment effects with a stratified Cox regression model, using the estimated propensity score to determine the strata. On the basis of reported information, these analyses appear to have used models with different baseline hazards for each stratum and a common treatment effect. The numbers of strata were 5 (1 analysis), 4 (3 analyses), or 2 (1 analysis).
Regression on the propensity score (20 analyses). None described the form of the outcome regression model that included the estimated propensity score as a covariate. In addition to the treatment indicator and estimated propensity score, 8 analyses also included other covariates in the model. Only 1 analysis used the estimated propensity score in a "doubly robust analysis"; however, specific details were not reported.
IPTW (4 analyses). Three analyses described using weights equal to the inverse of the estimated probability of receiving the treatment actually received to estimate the average treatment effect; relevant details for the fourth analysis were not provided.
DISCUSSION
Propensity score-based methods for estimating treatment effects are popular in studies of treatments for CAD because the outcomes of interest are rare and the factors that determine treatment choice are relatively well-understood and captured in medical records. After reviewing a random sample of studies using propensity scores to estimate causal effects of treatments for CAD, we identified several methodological shortcomings. By examining variable selection across studies, we found large variation in the covariates included in the propensity score models. Our scheme for organizing the covariates may be useful for informing variable selection in future investigations.
Valid inference on the causal effects of fixed exposures requires that the interventions and target of inference are welldefined; treatment groups are exchangeable; the probability of treatment conditional on covariates needed for exchangeability is positive; measurement error in exposures, outcomes, and covariates is accounted for; and missing data are handled appropriately. We discuss our findings in the context of these requirements.
Because the observed data alone cannot be used to determine whether the requirements for valid causal inference are met, sensitivity analyses should be performed to determine the potential impact on conclusions of lack of positivity, residual confounding, measurement error, and missing data (71) (72) (73) . Only one of the included studies reported formal sensitivity analyses for violations of the exchangeability assumption.
In comparative effectiveness studies, the target of inference (estimand) determines the appropriate methods for design and analysis. Arguably, studies using propensity scores for fixed treatments attempt to approximate the intention-to-treat effect that would be obtained in a nonblinded randomized trial with similar inclusion criteria. Of the studies reviewed, only 2 explicitly discussed the choice of estimand or the implications of that choice for handling treatment switching and loss to follow-up.
Investigators should carefully define the interventions of interest to clarify the scope of the analyses, allow an assessment of whether counterfactual outcomes are well-defined, and permit the assessment of other causal assumptions (74) . The studies reviewed often provided inadequate descriptions of the treatments being compared. This was particularly true for studies where medical therapy was one of the comparators of interest; these studies rarely specified the medical treatments (e.g., antithrombotic, lipid-lowering, or antihypertensive drugs) that comprised the intervention.
Positivity of treatment assignment (conditional on covariates) makes intuitive sense: To be able to draw inferences about the causal effect, as the sample size becomes arbitrarily large, treatment status should vary within strata defined by the confounding variables. Some information about positivity violations can be obtained by examining the distribution of the estimated propensity scores. For example, lack of overlap in the propensity score distributions of the treatment groups suggests that some combinations of baseline covariates make receiving one of the compared treatments unlikely. The included studies rarely reported comparisons of the propensity score distributions between treatment groups. More formal methods for detecting and responding to empirical positivity violations are also available (75, 76) but were not used in the studies we reviewed.
For valid causal inference, investigators using propensity score-based methods need to model the relationship between confounding variables and treatment to achieve conditional exchangeability of the treatment and control groups. Almost half of the studies reporting information on variable selection relied exclusively on statistical criteria for the association of covariates with treatment to select main effects, product terms, or nonlinear terms. Such criteria are inappropriate for building propensity score models because they pertain to the ability of covariates to predict exposure status and not their ability to reduce bias in the estimation of treatment effects. In fact, the very high C statistic values reported by some studies might indicate the inclusion of inappropriate variables in the propensity score model (e.g., instrumental or posttreatment variables) (77, 78) . Including instrumental variables in the propensity score increases the variance of the estimated treatment effects and may amplify bias (when residual confounding is present) (79, 80) ; including posttreatment variables can lead to selection bias (81, 82) . Furthermore, excluding certain variables from the propensity score model (e.g., those strongly associated with the treatment but weakly associated with the outcome) may improve variance without introducing serious bias. No studies explicitly considered this biasvariance trade-off (83) .
After categorizing the 400 covariates included in propensity score models into 60 coarser groups, only 3 groups were used by at least 80% of the studies, and only 17 were used by at least 50%. The diversity of included variables may indicate that failure to measure key covariates or inappropriate variable selection methods have left some studies vulnerable to residual confounding. Alternatively, researchers may have made a trade-off between bias and variance, in the way discussed above, without reporting relevant details. A third possibility is that different sets of variables were adequate for achieving (approximate) conditional exchangeability in different studies. This could happen if the causal structure varied across studies (9) or (even assuming a common causal structure) if multiple sets of variables were sufficient for confounding control. Regardless of the explanation for the observed diversity of included variables, future studies using propensity score models can use the covariate organization that we proposed to inform statistical or qualitative approaches for variable selection.
In general, the observed data cannot determine whether confounding has been fully controlled (84, 85) ; however, information about observed covariates can be obtained by assessing covariate balance after using the estimated propensity score. Balance in baseline covariates after using the propensity score was reported in only half of the studies. Balance assessments were based on mean comparisons and did not examine other features of the covariate distributions (e.g., higher order moments). Reporting of such assessments was associated with the methods used to estimate treatment effects, with 23 of the 27 analyses using matching versus 3 of the 29 analyses using other methods. This suggests that investigators are unfamiliar with the recommended methods for assessing balance when using methods other than matching (86, 87) .
No studies accounted for measurement error in exposures or outcomes. Such measurement error is likely, particularly in studies using routinely collected data, and can introduce bias of unpredictable direction and magnitude. Similarly, no studies accounted for measurement error in covariates included in the propensity score model. Although adjusting for multiple covariates can limit the impact of measurement error in some cases, some error is probably unavoidable and can manifest as residual confounding. When measurement error threatens study validity, it should be addressed with appropriate methods (88, 89) .
Missing data are common in medical data sets and can affect the interpretation of study results and introduce bias. Restricting analyses to study participants who do not have missing information on covariates limits the applicability of study findings to a somewhat ill-defined population. There is a growing literature on methods for handling missing data problems in the context of propensity score-based analyses (90) (91) (92) . Furthermore, missing data on the outcome can lead to bias (e.g., due to differential dropout). None of the studies we reviewed reported details about the handling of missing data.
Our study has several limitations. First, the literature search was not comprehensive, and we evaluated only a sample of publications. However, comprehensive coverage is not necessary for methodological appraisal, and random sampling allowed us to evaluate each study we included more carefully than would have been possible in a broader review. Second, incomplete reporting limited our ability to assess the methods used in the included studies. We suggest that both conduct and reporting are in need of improvement. Establishing minimum reporting standards for studies using propensity scores may indirectly lead to improvements in study conduct (such a pattern was noted after the adoption of reporting guidelines for clinical trials (93, 94) ). Third, we could not be certain about the details of variable coding and model specification. Variability in reporting of model specifications may have introduced data collection errors, but we do not believe that such errors would change the overall pattern of extreme model diversity. Fourth, we have not attempted to compare the results of observational studies using propensity scores versus randomized trials. At a minimum, such comparisons would require the interventions and outcomes, as well as the distribution of effect modifiers, to be the same across studies. Although such cross-study comparisons can be informative when the compared studies are very carefully matched (95, 96) , the data we collected could not support such matching. Rather, we believe that better information can be derived from empirical assessments using individual-level data to design observational studies emulating specific trials (5, 97) .
In summary, the conduct and reporting of studies using propensity scores in CAD is not consistent with current methodological standards. Broad agreement on standards for conducting and reporting observational studies using propensity scores would be a useful way forward.
